D.E. Shaw & Co
TVGNW icon

D.E. Shaw & Co’s Tevogen Bio Warrant TVGNW Stock Holding History

D.E. Shaw & Co’s Portfolio TVGNW Stock Details TVGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-307,999
Closed -$21.6K – 4899
2024
Q1 		$21.6K Hold
307,999
– – ﹤0.01% 4117
2023
Q4 		$12.3K Buy
307,999
+183,000
+146% +$7.43K ﹤0.01% 4103
2023
Q3 		$8.21K Hold
124,999
– – ﹤0.01% 4084
2023
Q2 		$5.15K Hold
124,999
– – ﹤0.01% 4109
2023
Q1 		$6.29K Hold
124,999
– – ﹤0.01% 4292
2022
Q4 		$937 Hold
124,999
– – ﹤0.01% 4794
2022
Q3 		$16K Hold
124,999
– – ﹤0.01% 4842
2022
Q2 		$20K Hold
124,999
– – ﹤0.01% 5011
2022
Q1 		$34K Buy
+124,999
New +$46.5K ﹤0.01% 5242

Other funds holding TVGNW

FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

D.E. Shaw & Co's TVGNW Position: Q2 2024 in Review

D.E. Shaw & Co sold out of Tevogen Bio Warrant (TVGNW) in Q2 2024, closing a stake of 307,999 shares — an estimated $21.6K sold.

D.E. Shaw & Co first reported a position in TVGNW in Q1 2022 and held it in 9 quarters. The position peaked at $34K in Q1 2022. 39 funds tracked by Wall St. Rank hold TVGNW as of Q2 2024.

  • D.E. Shaw & Co reported no remaining Tevogen Bio Warrant position as of Q2 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 307,999 Tevogen Bio Warrant shares in Q2 2024, an estimated $21.6K.
  • D.E. Shaw & Co first reported a position in Tevogen Bio Warrant in Q1 2022 and held it in 9 quarters.
  • D.E. Shaw & Co's Tevogen Bio Warrant position peaked at $34K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Tevogen Bio Warrant as of Q2 2024.

Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.